UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 374

Sortiert nach

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15)

Journal of antimicrobial chemotherapy, 2017-05, Vol.72 (5), p.1386-1395

2017

Link zum Volltext

Verfügbarkeit prüfen

Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016

Diagnostic microbiology and infectious disease, 2018-09, Vol.92 (1), p.69-74

2018

Link zum Volltext

Verfügbarkeit prüfen

In Vitro Potency and Spectrum of the Novel Polymyxin MRX-8 Tested against Clinical Isolates of Gram-Negative Bacteria

Antimicrobial agents and chemotherapy, 2022-05, Vol.66 (5), p.e0013922-e0013922

2022

Link zum Volltext

Verfügbarkeit prüfen

Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015

Antimicrobial agents and chemotherapy, 2018-03, Vol.62 (3)

2018

Link zum Volltext

Verfügbarkeit prüfen

In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe

Antimicrobial agents and chemotherapy, 2020-10, Vol.64 (11)

2020

Link zum Volltext

Verfügbarkeit prüfen

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)

Journal of antimicrobial chemotherapy, 2022-09, Vol.77 (10), p.2642-2649

2022

Link zum Volltext

Verfügbarkeit prüfen

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections

International journal of infectious diseases, 2021-12, Vol.113, p.279-281

2021

Link zum Volltext

Verfügbarkeit prüfen

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18

Journal of antimicrobial chemotherapy, 2020-10, Vol.75 (10), p.2907-2913

2020

Link zum Volltext

Verfügbarkeit prüfen

Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018−2020)

Diagnostic microbiology and infectious disease, 2023-01, Vol.105 (1), p.115820-115820, Article 115820

2023

Link zum Volltext

Verfügbarkeit prüfen

Antimicrobial activity of dalbavancin and comparators against Staphylococcus aureus causing pneumonia in patients with and without cystic fibrosis

International journal of infectious diseases, 2021-06, Vol.107, p.69-71

2021

Link zum Volltext

Verfügbarkeit prüfen

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16

Journal of antimicrobial chemotherapy, 2018-10, Vol.73 (10), p.2748-2756

2018

Link zum Volltext

Verfügbarkeit prüfen

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme

International journal of antimicrobial agents, 2019-05, Vol.53 (5), p.637-643

2019

Link zum Volltext

Verfügbarkeit prüfen

Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe

Antimicrobial agents and chemotherapy, 2020-04, Vol.64 (5)

2020

Link zum Volltext

Verfügbarkeit prüfen

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide

Antimicrobial agents and chemotherapy, 2020-10, Vol.64 (11)

2020

Link zum Volltext

Verfügbarkeit prüfen

Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018

Antimicrobial agents and chemotherapy, 2020-05, Vol.64 (6)

2020

Link zum Volltext

Verfügbarkeit prüfen

Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016

Antimicrobial agents and chemotherapy, 2019-01, Vol.63 (1)

2019

Link zum Volltext

Verfügbarkeit prüfen

Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5‑Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA

Journal of medicinal chemistry, 2021-10, Vol.64 (20), p.15214-15249

2021

Link zum Volltext

Verfügbarkeit prüfen

Ceftazidime–Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011–2015)

The Pediatric infectious disease journal, 2018-06, Vol.37 (6), p.549-554

2018

Link zum Volltext

Verfügbarkeit prüfen

Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers

Antimicrobial agents and chemotherapy, 2018-03, Vol.62 (3)

2018

Link zum Volltext

Verfügbarkeit prüfen

Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020

Diagnostic microbiology and infectious disease, 2022-07, Vol.103 (3), p.115713-115713, Article 115713

2022

Link zum Volltext

Verfügbarkeit prüfen

Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride

Diagnostic microbiology and infectious disease, 2017-12, Vol.89 (4), p.305-309

2017

Link zum Volltext

Verfügbarkeit prüfen

Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide

Journal of antimicrobial chemotherapy, 2020-06, Vol.75 (6), p.1518-1524

2020

Link zum Volltext

Verfügbarkeit prüfen

In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016)

Antimicrobial agents and chemotherapy, 2018-02, Vol.62 (2)

2018

Link zum Volltext

Verfügbarkeit prüfen

Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients

JAC-antimicrobial resistance, 2021-09, Vol.3 (3), p.dlab126-dlab126

2021

Link zum Volltext

Verfügbarkeit prüfen

Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016–2017)

Diagnostic microbiology and infectious disease, 2019-07, Vol.94 (3), p.304-313

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 374

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(318)
Mit Volltextzugriff
(338)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(373)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(186)
Life Sciences & Biomedicine
(155)
Humans
(112)
Female
(46)
Biological And Medical Sciences
(43)
Male
(42)
Pharmacology & Pharmacy
(38)
Infectious Diseases
(37)
Medical Sciences
(34)
Microbiology
(34)
Adult
(32)
Animals
(28)
Middle Aged
(25)
Physical Sciences
(24)
Aged
(21)
Chemistry
(21)
Microbial Sensitivity Tests
(21)
Anti-Bacterial Agents - Pharmacology
(18)
Mice
(18)
Social Sciences
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15)

Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016

In Vitro Potency and Spectrum of the Novel Polymyxin MRX-8 Tested against Clinical Isolates of Gram-Negative Bacteria

Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015

In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18

Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018−2020)

Antimicrobial activity of dalbavancin and comparators against Staphylococcus aureus causing pneumonia in patients with and without cystic fibrosis

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme

Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide

Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018

Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016

Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5‑Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA

Ceftazidime–Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011–2015)

Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers

Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020

Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride

Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide

In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016)

Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients

Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016–2017)

Suchergebnisse filtern